...
首页> 外文期刊>Radiology and Oncology >Lymphedema following cancer therapy in Slovenia: a frequently overlooked condition?
【24h】

Lymphedema following cancer therapy in Slovenia: a frequently overlooked condition?

机译:斯洛文尼亚癌症治疗后的淋巴水肿:经常被忽视的疾病吗?

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction. Secondary lymphedema following cancer therapy is a frequent, often painful, quality of life disturbing condition, reducing the patients' mobility and predisposing them to complications, e.g. infections and malignancies. The critical aspect of lymphedema therapy is to start as soon as possible to prevent the irreversible tissue damage.Patients and methods. We performed a retrospective study of patients with lymphedema, treated at the Department of Dermatovenereology, University Medical Center Ljubljana, from January 2002 to June 2010. The patients' demographic and medical data were collected, including type of cancer, type and stage of lymphedema, and time to first therapy of lymphedema. The number of referred patients with lymphedema following the therapy of melanoma, breast cancer, and uterine/cervical cancer, was compared to the number of patients expected to experience lymphedema following cancer therapy, calculated from the incidence reported in the literature.Results. In the period of 8.5 years, 543 patients (432 females, 112 males) with lymphedema were treated. The results show that probably many Slovenian patients with secondary lymphedema following cancer therapy remain unrecognized and untreated or undertreated. In the majority of our patients, the management of lymphedema was delayed; on average, the patients first received therapy for lymphedema 3.6 years after the first signs of lymphedema.Conclusions. To avoid a delay in diagnosis and therapy, and the complications of lymphedema following cancer therapy, the physician should actively look for signs or symptoms of lymphedema during the follow-up period, and promptly manage or refer the patients developing problems.
机译:介绍。癌症治疗后的继发性淋巴水肿是一种常见的,通常是痛苦的,影响生活质量的状况,降低了患者的活动能力并使他们容易发生并发症,例如:感染和恶性肿瘤。淋巴水肿治疗的关键方面是尽快开始以防止不可逆的组织损伤。患者和方法。我们对2002年1月至2010年6月在卢布尔雅那大学医学中心皮肤病学系治疗的淋巴水肿患者进行了回顾性研究。收集了患者的人口统计和医学数据,包括癌症类型,淋巴水肿的类型和分期,以及首次淋巴水肿治疗的时间。根据文献报道的发生率,将治疗后的黑色素瘤,乳腺癌和子宫/宫颈癌的淋巴水肿转诊患者人数与预期的癌症治疗后发生淋巴水肿的患者人数进行比较。在8.5年的时间里,治疗了543例淋巴水肿患者(432例女性,112例男性)。结果表明,可能有许多斯洛文尼亚癌症治疗后继发淋巴水肿的患者仍未被认识,未治疗或治疗不足。在我们大多数患者中,淋巴水肿的治疗被延迟;平均而言,患者在出现淋巴水肿的最初征兆后3.6年首次接受了淋巴水肿的治疗。为了避免诊断和治疗的延迟以及癌症治疗后出现淋巴水肿的并发症,医师应在随访期间积极寻找淋巴水肿的体征或症状,并及时处理或转诊出现问题的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号